FDA has requested that drug manufacturers remove suicidal ideation and behavior (SI/B) warnings from the labeling of three GLP-1 receptor agonist (GLP-1 RA) medications used for weight management: Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide)
2024;29(11):377 Kanamori M, Nakatsukasa H, Okada M, Lu Q, Yoshimura A
## How to Choose: A Decision Framework **Choose Semaglutide if** you want the most established safety profile, cardiovascular protection matters to you (SELECT trial data), you prefer the most affordable compounded option, or you are new to GLP-1 therapy and want a well-studied starting point
If you have a history of liver disease, consult your doctor before starting this medicine
Your healthcare provider is there to ensure your safety, especially during your first few attempts at reconstitution
Medicines and Healthcare products Regulatory Agency GOV.UK